Q-omics provides the consensus-scored TRAJ31 profile across patient tissues and cancer cell-line models. TRAJ31 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRAJ31 is differentially expressed in 5, with the highest sampling consensus in PAAD. Additionally, TRAJ31 RNA expression shows 11,715 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, PAAD, and LSCC as cancer lineages where TRAJ31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ31 survival associations across molecular data types. TRAJ31 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ31 RNA expression–survival associations across cancer types. High TRAJ31 expression shows unfavorable associations in ACC, KIRC, OV and ESCA, but favorable associations in CESC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRAJ31 RNA expression.
This table summarizes TRAJ31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ31 shows lower tumor expression in PAAD, UCEC and ESCA and higher tumor expression in KIRC and BRCA. The PAAD box plot shows higher TRAJ31 RNA expression in normal versus tumor tissue (log2 FC = −1.160, t-test p = .028).
This table shows molecular features associated with TRAJ31 in patient tissues and cancer cell lines. In patient samples, TRAJ31 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
